Akl, E., Fouad, N., Alamin, M., khalil, K. (2023). Serum Neprilysin Is a Significant Predictor of Metabolic Syndrome in Psoriasis Patients. The Egyptian Journal of Hospital Medicine, 91(1), 3902-3906. doi: 10.21608/ejhm.2023.294148
Essam Mohamed Akl; Nehad A. Fouad; Marwa Bashir Amir Alamin; Karem Taha khalil. "Serum Neprilysin Is a Significant Predictor of Metabolic Syndrome in Psoriasis Patients". The Egyptian Journal of Hospital Medicine, 91, 1, 2023, 3902-3906. doi: 10.21608/ejhm.2023.294148
Akl, E., Fouad, N., Alamin, M., khalil, K. (2023). 'Serum Neprilysin Is a Significant Predictor of Metabolic Syndrome in Psoriasis Patients', The Egyptian Journal of Hospital Medicine, 91(1), pp. 3902-3906. doi: 10.21608/ejhm.2023.294148
Akl, E., Fouad, N., Alamin, M., khalil, K. Serum Neprilysin Is a Significant Predictor of Metabolic Syndrome in Psoriasis Patients. The Egyptian Journal of Hospital Medicine, 2023; 91(1): 3902-3906. doi: 10.21608/ejhm.2023.294148
Serum Neprilysin Is a Significant Predictor of Metabolic Syndrome in Psoriasis Patients
dermatology andrology department, faculty of medicine benha university,egypt
Abstract
Background: There is a lot of disagreement on the connection between metabolic syndrome and psoriasis. A membrane-bound metallopeptidase with a wide variety of physiological uses is neprilysin (NEP). New information suggests that NEP may contribute to the aetiology of the metabolic syndrome. Objective: To evaluate serum NEP levels and their significance in the metabolic features of psoriasis patients. Patients and Methods: A total of fifty psoriasis patients and thirty healthy volunteers of matched age and sex participated in this case-control research. Every participant underwent clinical examination with focus on measuring the PASI score, blood pressure (systolic, SBP and diastolic, DBP), and abdominal circumference. Additionally, lipid profile, NEP, and fasting blood sugar (FBS) assays were performed. Results: In comparison to controls, psoriasis patients had significantly higher SBP, DBP, FBS, and triglycerides (p=0.01, 0.04, 0.04, and 0.01, respectively). Median level of NEP was 225.35pg/mL with range of 45.4-540.2pg/mL in psoriasis patients compared with controls (51.65, 41.6-368.9) (p <0.001). NEP showed significant positive correlation with PASI score (r=0.462, p=0.001). NEP was found to be the only predictor of the probability of metabolic syndrome in psoriasis patients (p < 0.001). Conclusion: NEP concentrations can be used as a marker to check for metabolic syndrome in psoriasis patients.
View on SCiNiTO
Top